Aurora Cannabis (Nasdaq:ACB) - Aandelenkoers, Nieuws & Analyse

ACB Overzicht aandelen

ACB fundamentele analyse
Sneeuwvlok Score
Waardering	6/6
Toekomstige groei	1/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Verhandeld tegen 88.3% onder onze schatting van de reële waarde

De omzet zal naar verwachting met 11.85% per jaar groeien

De winst is de afgelopen 5 jaar met 35.5% per jaar gegroeid

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Analisten zijn het erover eens dat de aandelenkoers met 52.1% zal stijgen

Risicoanalyse

Aandeelhouders zijn het afgelopen jaar verwaterd

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Aurora Cannabis Inc. Concurrenten

biote

NasdaqGM:BTMD

US$217.3m

Nektar Therapeutics

NasdaqCM:NKTR

US$193.7m

MediWound

NasdaqGM:MDWD

US$177.8m

Eton Pharmaceuticals

NasdaqGM:ETON

US$290.1m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Aurora Cannabis
Historische aandelenkoersen
Huidige aandelenkoers	CA$4.34
52 Week Hoogtepunt	CA$9.35
52 Week Laag	CA$2.84
Bèta	2.7
11 maand verandering	-26.81%
3 maanden verandering	-33.02%
1 Jaar Verandering	-9.19%
33 jaar verandering	-93.61%
5 jaar verandering	-98.55%
Verandering sinds IPO	-88.45%

Recent nieuws en updates

Recent updates

Aurora Cannabis: Revving Up To Profitability

Aug 08

Aurora launches new cannabis products for adult and medical-use

Oct 17

Aurora Cannabis further strengthens its balance sheet by repurchasing ~US$23M of convertible notes

Oct 07

Is Aurora Cannabis Stock A Buy Or Sell Before Upcoming Earnings? Buy The U.S. Opportunity

Sep 16

Aurora Cannabis Is A Pass For Now, Although We Are Bullish On The Industry

Jun 05

Aurora Cannabis: Extreme Downside Case Averted

Feb 02

Rendement voor aandeelhouders

	ACB	US Pharmaceuticals	US Markt
7D	3.3%	1.6%	2.2%
1Y	-9.2%	9.9%	31.6%

Rendement versus industrie: ACB presteerde slechter dan de US Pharmaceuticals -sector, die het afgelopen jaar een rendement van 9.9 % opleverde.

Rendement versus markt: ACB presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 31.6 % opleverde.

Prijsvolatiliteit

Is ACB's price volatile compared to industry and market?
ACB volatility
ACB Average Weekly Movement	8.3%
Pharmaceuticals Industry Average Movement	9.5%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: ACB heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van ACB is het afgelopen jaar gedaald van 15% naar 8%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2013	1,073	Miguel Martin	www.auroramj.com

Aurora Cannabis Inc. houdt zich samen met haar dochterondernemingen bezig met de productie, distributie en verkoop van cannabis en van cannabis afgeleide producten in Canada en internationaal. Het is actief in twee segmenten, Canadian Cannabis en Plant Propagation. Het bedrijf biedt medische en consumenten cannabisproducten aan, levert vermeerderde groenten en sierplanten en distribueert en verkoopt van hennep afgeleide cannabidiol (CBD) producten.

Aurora Cannabis Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Aurora Cannabis zich tot de beurswaarde?
ACB fundamentele statistieken
Marktkapitalisatie	US$237.38m
Inkomsten(TTM)	-US$21.29m
Inkomsten(TTM)	US$212.48m

1.1x

P/S-verhouding

-11.1x

Koers/Winstverhouding

Is ACB overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ACB resultatenrekening (TTM)
Inkomsten	CA$296.99m
Kosten van inkomsten	CA$139.24m
Brutowinst	CA$157.75m
Overige uitgaven	CA$187.52m
Inkomsten	-CA$29.76m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.54
Brutomarge	53.12%
Nettowinstmarge	-10.02%
Schuld/Eigen Vermogen Verhouding	9.9%

Hoe presteerde ACB op de lange termijn?

Bekijk historische prestaties en vergelijking

ACB Overzicht aandelen

Beloningen

Risicoanalyse

Aurora Cannabis Inc. Concurrenten

NasdaqGM:BTMD

US$217.3m

NasdaqCM:NKTR

US$193.7m

NasdaqGM:MDWD

US$177.8m

NasdaqGM:ETON

US$290.1m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Aurora Cannabis Inc. Expands Innovative Recreational Product Portfolio

New minor risk - Profitability

Forecast to breakeven in 2026

Aurora Cannabis Inc. Announces Notice of Proposed Settlement of Class Action Involving All Persons and Entities Who Purchased Aurora Cannabis Inc. Common Stock Between October 23, 2018 and February 28, 2020, Inclusive

Second quarter 2025 earnings released: EPS: CA$0.05 (vs CA$0.048 in 2Q 2024)

Aurora Cannabis Inc. to Report Q2, 2025 Results on Nov 06, 2024

Recent updates

Aurora Cannabis Inc. Expands Innovative Recreational Product Portfolio

New minor risk - Profitability

Forecast to breakeven in 2026

Aurora Cannabis Inc. Announces Notice of Proposed Settlement of Class Action Involving All Persons and Entities Who Purchased Aurora Cannabis Inc. Common Stock Between October 23, 2018 and February 28, 2020, Inclusive

Second quarter 2025 earnings released: EPS: CA$0.05 (vs CA$0.048 in 2Q 2024)

Aurora Cannabis Inc. to Report Q2, 2025 Results on Nov 06, 2024

Aurora Cannabis Inc. Announces Board Changes and Changes to Board Committee Compositions

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Aurora Cannabis: Revving Up To Profitability

Aurora Cannabis Inc. to Report Q1, 2025 Results on Aug 07, 2024

New minor risk - Profitability

Full year 2024 earnings released: CA$1.28 loss per share (vs CA$8.22 loss in FY 2023)

Forecast breakeven date pushed back to 2027

Aurora Cannabis Inc. Appoints Rajesh Uttamchandani to its Board of Directors

Aurora Cannabis Inc. in Conjunction with MedReleaf Australia, Announce Expansion of its Portfolio with Introduction of New Range of Premium Dried Cannabis Flower Products

New minor risk - Share price stability

Aurora Cannabis Inc. Announces CFO Changes

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Shareholder dilution

New minor risk - Profitability

Aurora Cannabis Inc. (TSX:ACB) acquired remaining 90% stake in Indica Industries Pty Ltd for AUD 45 million.

Aurora Cannabis Inc. Provides Earnings Guidance for the Fourth Quarter of Fiscal 2024

Aurora Cannabis Inc. to Report Q3, 2024 Results on Feb 08, 2024

Forecast to breakeven in 2026

New major risk - Financial position

Aurora Cannabis Inc. Provides Revenue Guidance for Third Quarter of Fiscal 2024

Aurora Cannabis Inc. to Report Q2, 2024 Results on Nov 09, 2023

New major risk - Shareholder dilution

Aurora Cannabis Inc. has completed a Follow-on Equity Offering in the amount of CAD 38.826875 million.

New major risk - Financial position

Aurora Cannabis Inc. Provides Revenue Guidance for the Second Quarter of Fiscal Year 2024

Aurora Cannabis Inc. to Report Q1, 2024 Results on Aug 10, 2023

Bevo Farms Ltd acquired Medicine Hat, Alberta Aurora Sun Facility from Aurora Cannabis Inc. (TSX:ACB) for CAD 15 million.

Now 21% undervalued after recent price drop

CEO & Director recently bought US$98k worth of stock

New minor risk - Profitability

Third quarter 2023 earnings released: CA$0.24 loss per share (vs CA$4.72 loss in 3Q 2022)

Aurora Cannabis Inc. to Report Fiscal Year 2023 Results on Jun 14, 2023

Aurora Celebrates Summer with New Innovation Launching Across Canada

Aurora Cannabis Inc., Annual General Meeting, Aug 14, 2023

Forecast to breakeven in 2026

Aurora Cannabis Inc. Reports Impairment Changes for the Quarter Ended December 31, 2022

Second quarter 2023 earnings released

Aurora Cannabis Inc. to Report Q2, 2023 Results on Feb 09, 2023

An Unknown buyer acquired Aurora Polaris facility from Aurora Cannabis Inc. for CAD15 million.

Now 20% undervalued after recent price drop

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Forecast to breakeven in 2025

First quarter 2023 earnings released: CA$0.17 loss per share (vs CA$0.06 loss in 1Q 2022)

Aurora Cannabis Inc. to Report Q1, 2023 Results on Nov 10, 2022

Aurora Announces Unprecedented Fall Product Release Across Adult-Use and Medical Markets

Aurora Announces Unprecedented Fall Product Release Across Adult-Use and Medical Markets

Aurora launches new cannabis products for adult and medical-use

Aurora Cannabis further strengthens its balance sheet by repurchasing ~US$23M of convertible notes

Full year 2022 earnings: Revenues in line with analyst expectations

Aurora Cannabis Q4 2022 Earnings Preview

Aurora Cannabis Inc. to Report Q4, 2022 Results on Sep 20, 2022

Aurora Cannabis Inc., Annual General Meeting, Nov 14, 2022

Aurora Cannabis Inc. (TSX:ACB) acquired 50.1% stake in Bevo Agtech Inc. for CAD 57 million.